This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Pfizer.
Reference
Holden SE, et al. Cost of dose escalation in people with rheumatoid arthritis treated with TNF inhibitors across Europe. Clinical and Experimental Rheumatology : 9 May 2016. Available from: URL: http://doi.org/9815 [pii]
Rights and permissions
About this article
Cite this article
TNF inhibitor dose escalation costly in RA. PharmacoEcon Outcomes News 754, 32 (2016). https://doi.org/10.1007/s40274-016-3102-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3102-5